home / stock / apm / apm news

APM News and Press, Aptorum Group Limited From 02/10/20

Stock Information
Company Name: Aptorum Group Limited
Stock Symbol: APM
Market: NASDAQ
Website: aptorumgroup.com
Menu
APM APM Quote APM Short APM News APM Articles APM Message Board
Get APM Alerts

News, Short Squeeze, Breakout and More Instantly...
APM - Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track Targeted For IND Submission in H2 2020

Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces further positive data from its current investigational new drug (IND)-enabling studies for ALS-4, ...
APM - Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020

Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces positive data and development in relation to its repurposed drug candidate, SACT-1, for the treatm...

APM - Aptorum Group Limited Announces Results of 2019 Annual General Meeting

Aptorum Group Limited (Nasdaq: APM) (“the Company”) a biopharmaceutical company focused on the development of novel therapeutics to address certain global unmet medical needs, announced today the results of its 2019 Annual General Meeting, which was held on November 14, 2019, in...

APM - Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma

Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of two preclinical drug candidates which target obesity and neuroblastoma, respect...
APM - Aptorum Group Limited reports 1H results

Aptorum Group Limited (NASDAQ: APM ): 1H GAAP EPS of -$0.31. More news on: Aptorum Group Limited, Earnings news and commentary, Read more ...

APM - Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2019

Aptorum Group Limited (“Aptorum Group” or the “Company”) (NASDAQ: APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today provided a business update and announced financial results for the six ...

APM - Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA

Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces that it has initiated investigational new drug (IND)-enabling studies for ALS-4, a small drug mole...
APM - Smart Pharma Token (SMPT) Debuts Its Initial Listing On IDAX: Global Blockchain Cryptocurrencies Trading Exchange Platform

Smart Pharma Group, a subsidiary group of Aptorum Group Limited (Nasdaq: APM), is excited to share that our Smart Pharma Token (“SMPT token”), traded publicly for the first time at 2:00 pm, 10 July 2019 (UTC+8:00), on IDAX ( https://www.idax.pro/ ). Trading is initially open for...

APM - Aptorum Group's subsidiary Smart Pharma announces Smart Pharma token (SMPT) to be listed on IDAX and LATOKEN

Aptorum Group Limited (Nasdaq: APM) subsidiary Smart Pharmaceutical is excited to announce that the Smart Pharma Token (“SMPT token”), is to be available for trading on IDAX ( https://www.idax.pro/ ) and LATOKEN ( https://latoken.com/ ). IDAX and LAtoken are two leading global c...

APM - Aptorum Group to Be Newly Added to MSCI HK Micro Cap Index

Aptorum Group Limited (Nasdaq: APM) (“the Company”) a pharmaceutical company dedicated to developing and commercializing a broad range of therapeutic and diagnostic technologies to tackle unmet medical needs, announced today the Company’s addition to the Morgan Stanley C...
Previous 10 Next 10